Breast Cancer Markers tests in Dubai & UAE

Compare available Breast Cancer Markers tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

Listed price range

750.00–2,000.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Breast Cancer Markers test prices

Showing 1–5 of 5 matching tests.

Breast Cancer Markers diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-1796 Breast Biopsy (Modified Radical Mastectomy) with ER, PR, HER2/neu, Ki‑67 Panel Test This diagnostic test evaluates the expression levels of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and the proliferation marker Ki-67 in breast cancer tissue.	Archival Surgical Tissue (FFPE Block / Slides from Modified Radical Mastectomy)	6 Days (Secure Medical Courier Retrieval inclusive)	1,700.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Estrogen Receptor (ER) expression", "Progesterone Receptor (PR) expression", "Human Epidermal Growth Factor Receptor 2 (HER2/neu) overexpression", "Ki-67 proliferation index"] Parameters [{"name": "Estrogen Receptor (ER)", "reference_range": "Scored using Allred score"}, {"name": "Progesterone Receptor (PR)", "reference_range": "Scored using Allred score"}, {"name": "HER2/neu", "reference_range": "Scored using ASCO/CAP guidelines (0, 1+, 2+, 3+)"}, {"name": "Ki-67", "reference_range": "Reported as percentage index"}] Preparation [] Indications ["Post-modified radical mastectomy breast cancer subtyping", "Guiding treatment decisions (hormonal, targeted, chemotherapy)", "Prognostic assessment"] Measurement technique Confirm with laboratory Codes LOINC: 85319-2 ICD-10: C50.9 Clinical summary This diagnostic test evaluates the expression levels of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and the proliferation marker Ki-67 in breast cancer tissue.
TEST-17 Breast Cancer ER, PR, HER-2, Ki-67 Panel Test This diagnostic test evaluates hormone receptor status (ER, PR), HER2 protein overexpression, and tumour cell proliferation (Ki-67) in breast cancer tissue.	Formalin-fixed paraffin-embedded (FFPE) tumour block or 10% neutral-buffered formalin tissue	10 working days	2,000.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Estrogen Receptor (ER) expression", "Progesterone Receptor (PR) expression", "HER2/neu protein overexpression", "Ki-67 proliferation index"] Parameters [{"name": "Estrogen Receptor (ER)", "reference_range": null}, {"name": "Progesterone Receptor (PR)", "reference_range": null}, {"name": "HER2/neu", "reference_range": null}, {"name": "Ki-67", "reference_range": null}] Preparation ["No fasting required", "No medication changes required"] Indications ["Diagnosis of breast cancer", "Prognosis assessment", "Prediction of response to targeted therapies", "Guidance for treatment planning (hormonal therapy, anti-HER2 therapy, chemotherapy)"] Measurement technique Confirm with laboratory Codes LOINC: 48600-0 ICD-10: C50.9 Clinical summary This diagnostic test evaluates hormone receptor status (ER, PR), HER2 protein overexpression, and tumour cell proliferation (Ki-67) in breast cancer tissue.
TEST-453 Breast Metastatic Marker Test This test evaluates serum levels of CA 15-3 and performs immunohistochemical profiling (ER, PR, HER2/neu, Ki-67) on tumour tissue.	Peripheral blood (serum) for CA 15‑3; Formalin‑fixed paraffin‑embedded (FFPE) tissue block for IHC and fragment analysis	Same day for CA 15‑3; 5‑7 business days for tissue components	750.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CA 15-3 (serum)", "Estrogen Receptor (ER) (tissue)", "Progesterone Receptor (PR) (tissue)", "HER2/neu (tissue)", "Ki-67 (tissue)", "Microsatellite Instability (optional, tissue)"] Parameters [{"name": "CA 15-3", "reference_range": null}, {"name": "ER", "reference_range": null}, {"name": "PR", "reference_range": null}, {"name": "HER2/neu", "reference_range": null}, {"name": "Ki-67", "reference_range": null}] Preparation ["No fasting required for blood draw", "Provide prior histopathology reports", "Provide exact biopsy site or block location for tissue retrieval"] Indications ["Detection of metastatic breast cancer", "Monitoring disease progression or response to therapy", "Prognostic assessment in breast cancer patients"] Measurement technique Confirm with laboratory Codes LOINC: 17877-9 ICD-10: Z85.3, R97.0, C50.919 Clinical summary This test evaluates serum levels of CA 15-3 and performs immunohistochemical profiling (ER, PR, HER2/neu, Ki-67) on tumour tissue.
TEST-492 CA 27.29 Breast Cancer Marker Test This diagnostic test evaluates the level of CA 27.29, a tumor marker associated with breast cancer, in the blood.	Serum or Plasma (Venous Blood)	2–3 weeks (14–21 business days)	1,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["MUC1 glycoprotein", "Tumor marker levels"] Parameters [{"name": "CA 27.29", "reference_range": null}] Preparation ["No fasting required", "Provide a brief clinical history", "Sign the mandatory consent form", "Disclose current medications, recent biopsies, or signs of infection"] Indications ["Monitoring breast cancer treatment response", "Detecting breast cancer recurrence", "Assessing cancer activity in metastatic settings"] Measurement technique Confirm with laboratory Codes LOINC: 10231-0 ICD-10: Z85.3, Z08.0 Clinical summary This diagnostic test evaluates the level of CA 27.29, a tumor marker associated with breast cancer, in the blood.
TEST-1526 HER-2/neu (Breast Cancer) Analysis Test This test evaluates the amplification status of the HER-2/neu gene in breast tumour tissue using Fluorescence In-Situ Hybridization (FISH). It provides a definitive positive or neg...	Formalin-fixed paraffin-embedded (FFPE) tumour tissue block or 4-micron unstained slides	7–8 working days	1,600.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["HER-2/neu gene copy number", "Gene amplification status"] Parameters [] Preparation ["No specific patient preparation required.", "Ensure adequate tumour tissue is available from biopsy or surgery."] Indications ["Diagnosis of invasive breast carcinoma", "Guidance for targeted therapy selection (e.g., trastuzumab)", "Resolution of equivocal IHC results"] Measurement technique Confirm with laboratory Codes LOINC: 49663-4 ICD-10: Z15.01, C50.9, Z85.3 Clinical summary This test evaluates the amplification status of the HER-2/neu gene in breast tumour tissue using Fluorescence In-Situ Hybridization (FISH). It provides a definitive positive or negative result regarding gene amplification.

Category overview

Breast Cancer Markers: overview

Facing a breast cancer diagnosis requires highly precise, tumor-specific insights to unlock the most effective, personalized treatment plan. As a critical offering within our advanced Histology department, Breast Cancer Markers testing (including ER, PR, HER2, and Ki-67) microscopically evaluates your biopsied tissue to understand exactly what is driving the tumor's growth. By leveraging state-of-the-art immunohistochemical technology, this vital cellular profiling provides the definitive data needed to safely guide life-saving hormone therapies, targeted biological treatments, and customized oncology care. Recognized for oncological diagnostic excellence among premier diagnostic labs in Dubai and the UAE, DNA Labs ensures strict patient confidentiality, uncompromising analytical precision, and remarkably fast turnaround times. Take control of your personalized cancer care—schedule your breast cancer markers testing in UAE, coordinate a secure clinical sample transfer, or consult our dedicated oncology specialists today.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.